Compare First Solar, Inc. (FSLR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Moderna, Inc. — how do they compare? First Solar, Inc. trades at $217.45 (market cap $24.05B), while Moderna, Inc. trades at $65.49 (market cap $27.09B). The key difference: First Solar, Inc. and Moderna, Inc. are close in size by market cap, and Moderna, Inc. is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals.
| FSLR | MRNA | |
|---|---|---|
Market Cap | $24.05B | $27.09B |
Sector | Technology | Health |
52-Week High | $318.30 | $81.80 |
52-Week Low | $166.82 | $22.36 |
Enterprise Value | $22.21B | $23.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $220.58, down 0.2% on the day, with a bearish technical signal driven by moving averages. The company shows strong fundamentals with a P/E of 14.46, net income margin of 30.73%, and robust cash flow from operations of $2.06B in 2025. Recent earnings beat in Q1 2026 but missed in prior quarters. Multiple class-action lawsuits filed in July 2026 allege securities fraud, creating near-term legal overhang.
The stock presents a mixed outlook: solid profitability and analyst consensus price target of $275.17 suggest upside, but legal risks and bearish technicals weigh. Investors face tension between strong financial health and potential volatility from litigation outcomes.
Moderna (MRNA) trades at $67.44, showing modest daily gains amid a bullish technical signal. The company continues to beat earnings expectations despite reporting significant net losses, with revenue declining from pandemic peaks to $1.92B in 2025. Recent positive developments include EU RSV vaccine contracts, Phase 1 cancer trial initiation, and FDA advisory panel support for its mRNA flu vaccine, driving recent stock momentum.
While Moderna's pipeline expansion beyond COVID-19 shows promise with oncology and rare disease applications, substantial financial risks persist with negative profit margins and cash burn. Analyst consensus remains cautious with a $49 price target below current levels, reflecting concerns about revenue sustainability versus pipeline execution risks and valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
